A phase II trial of personalized peptide vaccination for several cancer patients with slight bone marrow suppressio
Phase 2
- Conditions
- Cancer patients who are under standard treatments or resistant to standard treatments with slight bone marrow suppression
- Registration Number
- JPRN-UMIN000019390
- Lead Sponsor
- Kurume University Cancer Vaccine Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Not provided
Exclusion Criteria
The following patients must be excluded. 1)Patients with severe underlying diseases/ conditions(active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation etc.) 2)Patients with the past history of severe allergic reactions. 3)(Females) Pregnant or nursing patients. Patients desiring future fertility. (Males) Patients who do not accept contraception from the 1st vaccination until 70 days after the last vaccination. 4)Patients who are judged inappropriate for entry to this clinical trial by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of immunoresponses by mesurement of peptide specific IgGs
- Secondary Outcome Measures
Name Time Method 1.Safety assessment 2.Overall survival